Edesa Biotech, Inc. (EDSA) News
Follow Edesa Biotech, Inc. (EDSA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Edesa Biotech Receives FDA Clearance for Phase 2 Vitiligo Study
The FDA cleared the investigational new drug application for Edesa Biotech’s Phase 2 vitiligo study.
REGULATION | Oct 15, 2026, 01:15 PM UTC
M
AMLX, EDSA, QNBC price secondary share offerings
AMLX, EDSA and QNBC are among the names in a set of deals priced today, with AMLX pricing 14.1M shares at $35.50, EDSA 3.87M shares at $5.50 and QNBC 1.07M shares at $43.00.
MNA | Aug 20, 2026, 12:28 PM UTC
M
Edesa Biotech prices $25.0 million public offering
Edesa Biotech (EDSA) announces the pricing of a $25.0 million public offering.
EQUITY | Aug 20, 2026, 02:20 AM UTC
M
Edesa Biotech announces proposed public offering
Edesa Biotech (EDSA) announces a proposed public offering, with no offer size, pricing, or use of proceeds details provided in the alert.
EQUITY | Aug 19, 2026, 08:01 PM UTC
M
Edesa Biotech announces proposed public offering
Edesa Biotech announces a proposed public offering of its common stock; no size, pricing, or catalyst details were supplied in the alert.
MNA | Aug 19, 2026, 08:01 PM UTC
H
Edesa Biotech reports Fiscal 3rd Quarter 2026 results
Edesa Biotech (EDSA) reports its Fiscal 3rd Quarter 2026 results, according to TradeXchange Newsdesk, without any numbers or guidance details in the provided feed.
EQUITY | Aug 13, 2026, 08:15 PM UTC